Artificial organs最新文献

{"title":"Feasibility Testing of the 2nd Generation Inspired Therapeutics NeoMate System for Paracorporeal Support of Neonates and Infants in Heart Failure","authors":"Gretel Monreal,&nbsp;Steven C. Koenig,&nbsp;Mark S. Kelley,&nbsp;Joshua G. Crane,&nbsp;Isabelle R. Lytle,&nbsp;Jiapeng Huang,&nbsp;Mark S. Slaughter,&nbsp;Daniel G. White,&nbsp;Daniel Tamez,&nbsp;James F. Kelley","doi":"10.1111/aor.70155","DOIUrl":"10.1111/aor.70155","url":null,"abstract":"<div>\u0000 \u0000 \u0000 <section>\u0000 \u0000 <h3> Background</h3>\u0000 \u0000 <p>Inspired Therapeutics is advancing the development of the next generation of the NeoMate mechanical circulatory support (MCS) system for neonate and infant heart failure (HF) populations. The NeoMate system includes a low-cost magnetically-actuated paracorporeal centrifugal pump with an integrated, reusable motor and controller. This design iteration features a compact size (37 mm diameter), small prime volume (10 mL), and redesigned rotor and flow path. We present experimental data from computational fluid dynamics (CFD), mock loops, and acute animals.</p>\u0000 </section>\u0000 \u0000 <section>\u0000 \u0000 <h3> Methods</h3>\u0000 \u0000 <p>CFD models were used to improve pump design (wall shear stress, hemolysis index) and motor performance (torque, power, efficiency). Static mock loops (3.5 cP) were performed to evaluate hydrodynamics over a range of loads (0–300 mmHg) at 500–5500 rpm (<i>n</i> = 2 pumps tested, 24Fr inflow and 16Fr outflow cannula). A dynamic mock loop (3.5 cP) was tuned to HF, with the pump integrated LV apex-to-aorta and data collected from 0 to 5500 rpm. Two acute sheep studies were performed with each pump implanted paracorporeally: one LV apex-to-aorta (24Fr inflow, 16Fr outflow) and the other via the jugular vein (28Fr dual-lumen cannula).</p>\u0000 </section>\u0000 \u0000 <section>\u0000 \u0000 <h3> Results</h3>\u0000 \u0000 <p>CFD pump and motor performance and hemolysis index metrics were achieved exceeding design criteria (2.5 L/min, 150 mmHg) in static (2.5 L/min flow, 250 mmHg pressure), dynamic (2.8 L/min flow), and animals (3.1 L/min flow, 60 mmHg aortic pressure, plasma free hemoglobin &lt; 20 mg/dL) at 5500 rpm.</p>\u0000 </section>\u0000 \u0000 <section>\u0000 \u0000 <h3> Conclusions</h3>\u0000 \u0000 <p>The next generation NeoMate pumps demonstrated favorable hydrodynamic, hemodynamic, and blood trauma performance, showing promising progress toward this technology to serve as a versatile therapy for neonates and infants.</p>\u0000 </section>\u0000 </div>","PeriodicalId":8450,"journal":{"name":"Artificial organs","volume":"50 8","pages":"1182-1189"},"PeriodicalIF":2.2,"publicationDate":"2026-08-08","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"147760922","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Comparison of a Miniaturized Implantable Two-Stage Rotodynamic Blood Pump to Equivalent Single-Stage Concepts","authors":"Sarah Linnemeier,&nbsp;Bente Thamsen,&nbsp;Stefan Maric,&nbsp;Bernhard Semlitsch,&nbsp;Benjamin Torner,&nbsp;Daniel Zimpfer,&nbsp;Marcus Granegger","doi":"10.1111/aor.70152","DOIUrl":"10.1111/aor.70152","url":null,"abstract":"<div>\u0000 \u0000 \u0000 <section>\u0000 \u0000 <h3> Background</h3>\u0000 \u0000 <p>Hemocompatibility-related adverse events still limit the broader adoption of rotodynamic blood pumps. This study aims to evaluate the potential of a multistage pump design to enhance hemocompatibility in left ventricular assist devices.</p>\u0000 </section>\u0000 \u0000 <section>\u0000 \u0000 <h3> Methods</h3>\u0000 \u0000 <p>Computational fluid dynamic simulations were utilized to compare the pump performance and hemocompatibility of a Two-Stage Pump to two equivalent single-stage devices, designed for identical operating conditions. One single-stage design features equal impeller and volute dimensions; the other, equal specific speed and specific diameter. Our simulation setup was validated against in vitro experiments of the pump performance of the Two-Stage Pump.</p>\u0000 </section>\u0000 \u0000 <section>\u0000 \u0000 <h3> Results</h3>\u0000 \u0000 <p>The Two-Stage Pump achieved a substantial reduction in circumferential velocity (24% and 29% reduction). Although the two-stage configuration thereby effectively reduces shear stress, it simultaneously translates to a longer residence time due to the larger priming volume. However, because the numerical blood damage estimation weighs shear stress exponentially more than residence time, the beneficial effect of reduced shear stress partially compensates for the longer residence time. As a result, the Two-Stage Pump demonstrates a lower hemolysis index (12% and 14% reduction) compared to both single-stage designs.</p>\u0000 </section>\u0000 \u0000 <section>\u0000 \u0000 <h3> Conclusion</h3>\u0000 \u0000 <p>Our comparative study demonstrates that the two-stage concept offers favorable hemolysis measures compared to single-stage designs, as the reduction in peak shear stresses outweighs the disadvantage associated with prolonged residence time.</p>\u0000 </section>\u0000 </div>","PeriodicalId":8450,"journal":{"name":"Artificial organs","volume":"50 8","pages":"1125-1135"},"PeriodicalIF":2.2,"publicationDate":"2026-08-08","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://onlinelibrary.wiley.com/doi/epdf/10.1111/aor.70152","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"147810014","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Anticoagulation on ECMO Support: Time to Rethink Tradition","authors":"Patrick M. Wieruszewski,&nbsp;Jacopo D’Andria Ursoleo,&nbsp;Justyna Swol","doi":"10.1111/aor.70177","DOIUrl":"10.1111/aor.70177","url":null,"abstract":"&lt;p&gt;Extracorporeal membrane oxygenation (ECMO) has revolutionized the care of patients with refractory cardiopulmonary failure. However, because blood is in continuous contact with its artificial surfaces, ECMO introduces many untoward hemostatic disturbances [&lt;span&gt;1&lt;/span&gt;]. While heparin anticoagulation has been used since ECMO's inception and is considered effective in maintaining proper circuit function, this has been largely on the basis of experience and convenience, rather than rigorous comparative trials.&lt;/p&gt;&lt;p&gt;In this issue of &lt;i&gt;Artificial Organs&lt;/i&gt;, Scharner et al. report a systematic review with meta-analysis designed to evaluate the available evidence regarding efficacy and safety of various anticoagulation strategies in adults supported by ECMO [&lt;span&gt;2&lt;/span&gt;]. They identified 21 comparative studies that assessed heparin, direct thrombin inhibitors, low molecular weight heparins, nafamostat, and no anticoagulation. In random-effects meta-analysis, they found direct thrombin inhibitors (odds ratio [OR] 0.73, 95% confidence interval [CI] 0.53–0.99) and low molecular weight heparins (OR 0.26, 95% CI 0.13–0.55) to have lower odds of thrombotic events compared to heparin. Similarly, bleeding was less with direct thrombin inhibitors (OR 0.51, 95% CI 0.39–0.67) and low molecular weight heparins (OR 0.46, 95% CI 0.25–0.87). Importantly, the pooled effect estimates were only informed by observational studies, and most were judged to be of moderate to high risk of bias. Additionally, the analysis is limited by lack of a systematic certainty of evidence assessment. This is critical because although they found that certain pooled estimates suggested statistically significant treatment effects, without application of tools like the GRADE (Grading of Recommendations, Assessment, Development, and Evaluations) framework, the confidence of those estimates and what it means for clinical decision-making remains unanswered. Nonetheless, Scharner et al. should be congratulated on their effort which represents a substantial step forward for hemostatic management during ECMO support. However, many clinicians and researchers may continue to ask what is the most beneficial anticoagulant for ECMO support?&lt;/p&gt;&lt;p&gt;Heparin has long been considered the &lt;i&gt;de facto&lt;/i&gt; anticoagulant for ECMO support; however, many key pharmacological characteristics limit its true utility in this setting, thus prompting exploration of other options [&lt;span&gt;3&lt;/span&gt;]. Indeed, the findings of Scharner et al. suggest that heparin may be outpaced by other anticoagulants in the setting of ECMO. Direct thrombin inhibitors offer inhibition of freely circulating and clot-bound thrombin, the latter of which is particularly interesting during ECMO support and may explain Scharner et al.'s findings of reduced thrombotic events with their use compared to heparin. However, it is important to recognize that not all agents are created equal, as bivalirudin and argatroban have distinct pharmacol","PeriodicalId":8450,"journal":{"name":"Artificial organs","volume":"50 8","pages":"1101-1102"},"PeriodicalIF":2.2,"publicationDate":"2026-08-08","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://onlinelibrary.wiley.com/doi/epdf/10.1111/aor.70177","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"148026312","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Disembodied Human Brains Used in New Startup","authors":"Maria C. Beyer","doi":"10.1111/aor.70191","DOIUrl":"https://doi.org/10.1111/aor.70191","url":null,"abstract":"","PeriodicalId":8450,"journal":{"name":"Artificial organs","volume":"50 8","pages":""},"PeriodicalIF":2.2,"publicationDate":"2026-08-08","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"148695983","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Metabolic Conditioning for Renal Protection During Cardiopulmonary Bypass: A Narrative Review","authors":"Youssef El Dsouki,&nbsp;Patrick Hallak,&nbsp;Ignazio Condello,&nbsp;Roberto Lorusso","doi":"10.1111/aor.70133","DOIUrl":"10.1111/aor.70133","url":null,"abstract":"&lt;div&gt;\u0000 \u0000 \u0000 &lt;section&gt;\u0000 \u0000 &lt;h3&gt; Background&lt;/h3&gt;\u0000 \u0000 &lt;p&gt;Acute kidney injury (AKI) remains one of the most frequent and prognostically relevant complications following cardiac surgery, even in the era of modern cardiopulmonary bypass (CPB) management and goal-directed perfusion. Cardiac surgery–associated AKI (CSA-AKI) is associated with increased postoperative morbidity, prolonged hospitalization, neurocognitive complications, and reduced early as well as long-term survival. Although optimization of macrocirculatory parameters and oxygen delivery has demonstrated benefits, renal injury often occurs despite apparently adequate perfusion and oxygenation. Recent evidence suggests that CPB-related metabolic stress and protein catabolism contribute to renal vulnerability. Indeed, intravenous amino acid administration has emerged as a novel metabolic strategy for renal protection.&lt;/p&gt;\u0000 &lt;/section&gt;\u0000 \u0000 &lt;section&gt;\u0000 \u0000 &lt;h3&gt; Materials and Methods&lt;/h3&gt;\u0000 \u0000 &lt;p&gt;This narrative review was informed by a structured literature search of PubMed/MEDLINE, Embase, and the Cochrane Library, covering publications from database inception through March 2025. Search terms included combinations of “acute kidney injury,” “cardiac surgery,” “cardiopulmonary bypass,” “amino acids,” “intravenous amino acid infusion,” “renal protection,” and “goal-directed perfusion”. Randomized controlled trials, meta-analyses, systematic reviews, secondary analyses, and relevant narrative reviews published in English were considered. Particular emphasis was placed on high-quality evidence, including the PROTECTION randomized trial, contemporary meta-analyses, and consensus or expert reviews addressing cardiac surgery–associated acute kidney injury and perioperative metabolic interventions.&lt;/p&gt;\u0000 &lt;/section&gt;\u0000 \u0000 &lt;section&gt;\u0000 \u0000 &lt;h3&gt; Results&lt;/h3&gt;\u0000 \u0000 &lt;p&gt;The literature search identified 124 records; 18 articles were included in the final narrative synthesis after title, abstract, and full-text evaluation. The selected literature comprised a multicenter randomized controlled trial, secondary analyses of randomized data, meta-analyses/systematic reviews, narrative or expert reviews, and observational or mechanistic studies addressing CSA-AKI. The evidence indicates that CSA-AKI results from an interaction between altered renal perfusion, inflammation, ischemia–reperfusion injury, and CPB-induced metabolic derangement. Intravenous amino acid infusion was consistently associated with reduced postoperative AKI incidence, particularly in patients with preexisting chronic kidney disease, without significant safety concerns. These findings support amino acid administration as a metabolic adjunct to goal-directed perfusion rather than a standalone intervention.&lt;/p&gt;\u0000 &lt;/section&gt;\u0000 \u0000 &lt;section&gt;","PeriodicalId":8450,"journal":{"name":"Artificial organs","volume":"50 8","pages":"1118-1124"},"PeriodicalIF":2.2,"publicationDate":"2026-08-08","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"147728116","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Impact of Gentamicin-Impregnated Collagen Sponge on the Incidence of Access Related Infections After Full-Support Microaxial Flow Pump Therapy","authors":"Gaik Nersesian,&nbsp;Maximilian Rauch,&nbsp;Daniel Lewin,&nbsp;Leonard Pitts,&nbsp;Julius Kaemmel,&nbsp;Anna Stegmann,&nbsp;Julia Stein,&nbsp;Yuriy Hrytsyna,&nbsp;Felix Schoenrath,&nbsp;Volkmar Falk,&nbsp;Evgenij Potapov,&nbsp;Pia Lanmueller","doi":"10.1111/aor.70141","DOIUrl":"10.1111/aor.70141","url":null,"abstract":"<div>\u0000 \u0000 \u0000 <section>\u0000 \u0000 <h3> Background</h3>\u0000 \u0000 <p>Surgically implanted microaxial flow pumps (mAFP) are increasingly used for cardiogenic shock treatment. Standard mAFP explantation is performed bedside with a shortening of the vascular prosthesis, which may represent a potential source of infection in future. We analyzed the impact of gentamicin-impregnated collagen sponge (GICS) application in the wound during mAFP explantation on the incidence of prosthetic graft infections.</p>\u0000 </section>\u0000 \u0000 <section>\u0000 \u0000 <h3> Methods</h3>\u0000 \u0000 <p>Between 01/2020 and 07/2024, 235 patients underwent bedside full-support mAFP explantation at our institution. Since 11/2022, GICS has been routinely applied in 115 patients, while 120 previously were treated without it.</p>\u0000 </section>\u0000 \u0000 <section>\u0000 \u0000 <h3> Results</h3>\u0000 \u0000 <p>In the GICS-group, after a median follow-up of 221 [24; 351] days, 17 (14.8%) patients developed graft infection, resulting in 0.23 events per patient year (EPPY); surgery was necessary in 16 patients (13.9%). In the control group, after a median follow-up of 399 [113; 654] days, infection occurred in 14 (11.7%) cases, 0.10 EPPY; surgical removal of the graft was necessary in 12 (10%). The GICS-groups presented an increased risk for graft infections: sHR 2.49 [1.11; 5.59], <i>p</i> = 0.027. After propensity score matching for relevant demographic parameters, there was no significant difference in the risk reduction of total graft infections sHR 1.92 [0.79; 4,72], <i>p</i> = 0.15.</p>\u0000 </section>\u0000 \u0000 <section>\u0000 \u0000 <h3> Conclusions</h3>\u0000 \u0000 <p>Local application of GICS did not reduce the risk of access site infections in patients undergoing bedside explantation of mAFP from the graft surgically anastomosed to an axillary artery.</p>\u0000 </section>\u0000 </div>","PeriodicalId":8450,"journal":{"name":"Artificial organs","volume":"50 8","pages":"1153-1163"},"PeriodicalIF":2.2,"publicationDate":"2026-08-08","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://onlinelibrary.wiley.com/doi/epdf/10.1111/aor.70141","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"147761020","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Comparison of Left Ventricular Pressure-Volume Loops With Veno-Arterial Extracorporeal Membrane Oxygenator Support: In Vitro Investigation","authors":"Eric L. Wu,&nbsp;Johannes Boesch,&nbsp;Hideaki Nonaka,&nbsp;Christopher Djelovic,&nbsp;Avishka Wickramarachchi,&nbsp;Jessica Benitez,&nbsp;John F. Fraser","doi":"10.1111/aor.70163","DOIUrl":"10.1111/aor.70163","url":null,"abstract":"<div>\u0000 \u0000 \u0000 <section>\u0000 \u0000 <h3> Background</h3>\u0000 \u0000 <p>The hemodynamic consequence of increasing veno-arterial extracorporeal membrane oxygenator (V-A ECMO) flow on left ventricular (LV) loading is controversial, with in vivo studies reporting conflicting results on left ventricular distension. We investigated increased V-A ECMO flow on LV pressure-volume characteristics under varying cardiac and volume conditions using a repeatable in vitro mock circulation loop (MCL).</p>\u0000 </section>\u0000 \u0000 <section>\u0000 \u0000 <h3> Methods</h3>\u0000 \u0000 <p>A MCL was configured with V-A ECMO system to simulate four cardiogenic shock patients due to decompensated chronic heart failure patient: (1) LV failure with healthy right ventricle (RV) at normal volume (mean circulatory filling pressure, MCFP: 7 mmHg), (2) combined LV and RV failure at normal volume, (3) LV failure with healthy RV and volume overload (MCFP: 12 mmHg), and (4) combined LV and RV failure with volume overload. For each condition, ECMO flow was increased from 2 L/min to 4 L/min, and systemic vascular resistance (SVR) was adjusted to evaluate effects on LV pressure-volume loops.</p>\u0000 </section>\u0000 \u0000 <section>\u0000 \u0000 <h3> Results</h3>\u0000 \u0000 <p>In LV failure with preserved RV function with normal volume, increased ECMO flow at constant SVR led to LV distension (&gt; 30 mL increase in end-diastolic volume). Reducing SVR mitigated this effect but resulted in hypotension (MAP &lt; 65 mmHg). In combined LV and RV failure at normal volume, LV distension was less pronounced and manageable with SVR reduction while maintaining adequate MAP. Under volume overload, ECMO flow increases caused marked LV dilation and elevated central venous pressure, risking venous congestion.</p>\u0000 </section>\u0000 \u0000 <section>\u0000 \u0000 <h3> Conclusions</h3>\u0000 \u0000 <p>We demonstrated that LV distension during V-A ECMO flow is influenced by ventricular function, volume status, and SVR. Judicious volume management and afterload control are essential, and patients with preserved RV function may require adjunct LV unloading strategies.</p>\u0000 </section>\u0000 </div>","PeriodicalId":8450,"journal":{"name":"Artificial organs","volume":"50 8","pages":"1190-1196"},"PeriodicalIF":2.2,"publicationDate":"2026-08-08","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"147986235","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Recent Progress in the Field of Artificial Organs","authors":"","doi":"10.1111/aor.70192","DOIUrl":"https://doi.org/10.1111/aor.70192","url":null,"abstract":"","PeriodicalId":8450,"journal":{"name":"Artificial organs","volume":"50 8","pages":"1095-1096"},"PeriodicalIF":2.2,"publicationDate":"2026-08-08","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"148696059","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Toward Optimal Remote Monitoring in LVAD Recipients: Remaining Challenges Beyond Feasibility","authors":"Teruhiko Imamura","doi":"10.1111/aor.70189","DOIUrl":"10.1111/aor.70189","url":null,"abstract":"&lt;p&gt;I read with great interest the present paper, in which the authors conducted a nationwide multicenter analysis evaluating dedicated telemonitoring for patients with left ventricular assist devices (LVADs) using the Satelia LVAD platform [&lt;span&gt;1&lt;/span&gt;]. The study demonstrated the feasibility and potential clinical applicability of remote follow-up in a complex advanced heart failure population. Several points merit further discussion.&lt;/p&gt;&lt;p&gt;The clinical relevance of the detected alerts would benefit from additional clarification. Although the authors reported a large number of orange and red alerts, the study did not clarify how many alerts actually resulted in hospitalization, medication adjustment, outpatient intervention, or prevention of adverse events [&lt;span&gt;1&lt;/span&gt;]. Because alarm fatigue is a major limitation of telemonitoring systems, additional analyses regarding the positive predictive value, false-positive burden, and clinical consequences of each alert category would further enhance its practical implications [&lt;span&gt;2&lt;/span&gt;].&lt;/p&gt;&lt;p&gt;The study evaluated feasibility rather than hard clinical outcomes [&lt;span&gt;1&lt;/span&gt;]. The reported mortality rate of 30.6% during follow-up appears relatively high. However, there was no control group receiving standard-care without telemonitoring. Accordingly, as mentioned in the limitation section, it remains uncertain whether the application improved clinical outcomes compared with conventional follow-up strategies. Future comparative studies including standard-care control cohorts may help further define the clinical impact of telemonitoring in this population, particularly given the controversial findings reported in previous studies [&lt;span&gt;3&lt;/span&gt;].&lt;/p&gt;&lt;p&gt;The telemonitoring algorithm was primarily based on patient-reported symptoms and body weight rather than direct device telemetry [&lt;span&gt;1&lt;/span&gt;]. Future studies incorporating objective device-derived parameters, such as pump power, flow estimates, alarm data, or hemodynamic information, may further enhance risk stratification and improve the early detection of LVAD-related complications. Integration of these data with telemonitoring platforms may provide a more comprehensive assessment of patient status and help optimize remote management strategies in LVAD recipients [&lt;span&gt;3&lt;/span&gt;].&lt;/p&gt;&lt;p&gt;Caregiver participation likely played an important role in maintaining the remarkably high compliance rate of approximately 79% [&lt;span&gt;1&lt;/span&gt;]. However, caregiver burden, digital literacy, socioeconomic disparities, and accessibility to remote technologies were not systematically evaluated [&lt;span&gt;4&lt;/span&gt;]. These factors may substantially influence the generalizability and sustainability of telemonitoring programs, particularly in elderly or socially vulnerable populations. Further investigation of these social and practical aspects may help optimize future implementation of telemonitoring strategies in broader real-world settings.&lt;/p&gt;&lt;p&gt;The author take","PeriodicalId":8450,"journal":{"name":"Artificial organs","volume":"50 8","pages":"1197-1198"},"PeriodicalIF":2.2,"publicationDate":"2026-08-08","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://onlinelibrary.wiley.com/doi/epdf/10.1111/aor.70189","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"148275557","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"In Vitro Hemolytic Performance of the Novel Realheart Total Artificial Heart Versus SynCardia Total Artificial Heart With Human Blood","authors":"Shaikh Faisal Zaman,&nbsp;Kerstin Jönsson Videsäter,&nbsp;Thomas Finocchiaro,&nbsp;Oliver Voigt,&nbsp;Ina Laura Perkins","doi":"10.1111/aor.70149","DOIUrl":"10.1111/aor.70149","url":null,"abstract":"<div>\u0000 \u0000 \u0000 <section>\u0000 \u0000 <h3> Background</h3>\u0000 \u0000 <p>The SynCardia Total Artificial Heart (TAH) is FDA-approved for bridge to transplantation and has been implanted in over 2000 patients. While hemolysis has been reported postimplantation, no published in vitro test data assess hemolysis or hematology. The Realheart TAH is a novel four-chamber pulsatile positive displacement TAH which mimics the natural heart's atrioventricular plane movement for physiological flow patterns and gentle blood handling. This study evaluates in vitro hemolytic performance of the SynCardia TAH against a newer prototype of the Realheart TAH, V11.2, using human blood.</p>\u0000 </section>\u0000 \u0000 <section>\u0000 \u0000 <h3> Methods</h3>\u0000 \u0000 <p>Hemolysis testing followed ASTM standards, F1830-97 and F1841-97 (2017) using pooled human whole blood diluted to a hematocrit of 30% ± 2%. The targeted flow and pressure head were 5 ± 0.25 L/min and 100 mmHg, respectively. Hematology parameters were analyzed, plasma free hemoglobin (pfHb) was measured, and milligram normalized index of hemolysis (mgNIH) and modified index of hemolysis (MIH) were calculated. Statistical analyses were performed.</p>\u0000 </section>\u0000 \u0000 <section>\u0000 \u0000 <h3> Results</h3>\u0000 \u0000 <p>Mean mgNIH (<i>n</i> = 6) were 18.11 ± 3.53 mg/100 L for V11.2 and 37.15 ± 12.42 mg/100 L for SynCardia (<i>p</i> &lt; 0.05), a 2.05-fold increase in SynCardia TAH. MIH values were 1.69 ± 0.31 for V11.2 and 3.67 ± 1.29 for SynCardia (<i>p</i> &lt; 0.05). Compared with the static control, SynCardia significantly reduced erythrocyte and increased platelet counts, effects not observed with the V11.2, whereas V11.2 significantly reduced leukocyte counts relative to the control.</p>\u0000 </section>\u0000 \u0000 <section>\u0000 \u0000 <h3> Conclusion</h3>\u0000 \u0000 <p>Realheart TAH V11.2 exhibited significantly lower hemolysis than SynCardia TAH in a modified systemic circulation test rig, indicating better hemocompatibility.</p>\u0000 </section>\u0000 </div>","PeriodicalId":8450,"journal":{"name":"Artificial organs","volume":"50 8","pages":"1136-1144"},"PeriodicalIF":2.2,"publicationDate":"2026-08-08","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"147727949","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}